Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Marshall C. Freeman"'
Autor:
Andrew M. Blumenfeld, Richard J. Stark, Marshall C. Freeman, Amelia Orejudos, Aubrey Manack Adams
Publikováno v:
The Journal of Headache and Pain, Vol 19, Iss 1, Pp 1-12 (2018)
Abstract Background OnabotulinumtoxinA is approved for the prevention of headache in those with chronic migraine (CM); however, more clinical data on the risk-benefit profile for treatment beyond one year is desirable. Methods The Chronic Migraine On
Externí odkaz:
https://doaj.org/article/e5f92287e0ed4c8b8da7f9d5baf8c78d
Autor:
Daniel D. Mikol, Feng Zhang, Paul Winner, Jan Lewis Brandes, Robert A. Lenz, Marshall C. Freeman, Hans-Christoph Diener, Shannon Ritter, David Dolezil, Peter McAllister, Jan Klatt, Shihua Wen, Sunfa Cheng
ObjectiveTo assess the efficacy of erenumab across the spectrum of response thresholds (≥50%, ≥75%, 100%) based on monthly migraine days (MMD) reduction in patients with chronic migraine from a 12-week, randomized study (NCT02066415).MethodsPatie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c28e0db59391e008044596675ad9e1c9
https://duepublico2.uni-due.de/receive/duepublico_mods_00071866
https://duepublico2.uni-due.de/receive/duepublico_mods_00071866
Autor:
Amelia Orejudos, Marshall C. Freeman, Richard J Stark, Aubrey Manack Adams, Andrew M. Blumenfeld
Publikováno v:
The Journal of Headache and Pain
The Journal of Headache and Pain, Vol 19, Iss 1, Pp 1-12 (2018)
The Journal of Headache and Pain, Vol 19, Iss 1, Pp 1-12 (2018)
Background OnabotulinumtoxinA is approved for the prevention of headache in those with chronic migraine (CM); however, more clinical data on the risk-benefit profile for treatment beyond one year is desirable. Methods The Chronic Migraine Onabotulinu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb773c83dc7138bc5efece4643ecd851
http://europepmc.org/articles/PMC5799088
http://europepmc.org/articles/PMC5799088
Autor:
Robert D. Black, Deborah K. Attix, David T. Wilkinson, Dianne L. Scott, Mohamed Sakel, Daniel T. Laskowitz, Kathryn P. Poynter, Martin D. Slade, Kristen K. Ade, Lanty L. Smith, Maragatha Kuchibhatla, Lesco L. Rogers, Marshall C. Freeman, Anne H. Calhoun, Joel R. Saper, Michael E. Hoffer
Publikováno v:
Headache. 57(7)
Objective: To evaluate the safety and efficacy of a novel solid-state, caloric vestibular stimulation (CVS) device to provide adjuvant therapy for the prevention of episodic migraine in adult migraineurs. Background: Migraine causes significant disab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b67c47c158198fd1698f0bff961917b0
https://pubmed.ncbi.nlm.nih.gov/28656612
https://pubmed.ncbi.nlm.nih.gov/28656612
Autor:
Jessica O. Heiring, Sheena K. Aurora, Amanda M. VanDenburgh, Marshall C. Freeman, Paul Winner, Ronald E. DeGryse, Egilius L.H. Spierings, Catherine C. Turkel, Marissa E. Nolan
Publikováno v:
Headache. 51(9)
Objective.— To evaluate safety and efficacy of onabotulinumtoxinA (BOTOX®) as headache prophylaxis in adults with chronic migraine. Background.— Chronic migraine is a prevalent, disabling, and undertreated neurological disorder. Onabotulinumtoxi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::230b35fdacb4b61bb719bb251ad6f453
https://pubmed.ncbi.nlm.nih.gov/21883197
https://pubmed.ncbi.nlm.nih.gov/21883197
Publikováno v:
Headache. 49(2)
Background.— Since November 2002, Headache Wellness Center, a specialty headache practice in Greensboro, NC, has used exclusively an electronic medical record (EMR) system for all patient clinical contacts. Objective.— To assess patient satisfact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee501da71cd8157ae1cb2b33808ba6b2
https://pubmed.ncbi.nlm.nih.gov/18179567
https://pubmed.ncbi.nlm.nih.gov/18179567
Publikováno v:
Headache. 47(8)
Objective.—This case series is a retrospective chart analysis conducted to evaluate the efficacy of duloxetine as a migraine preventive medication and to suggest possible predictors of response. Background.— Duloxetine, a relatively new selective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edb160e70990cc52e8260e5c9a7b7f8c
https://pubmed.ncbi.nlm.nih.gov/17883526
https://pubmed.ncbi.nlm.nih.gov/17883526
Publikováno v:
Headache. 44(10)
Migraine preventive medications considered effective reduce headache frequency by 50 percent in approximately 50 percent of treated patients. In spite of similar effectiveness, these medications vary tremendonsly in their prices. Knowledge of medicat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0957e357f6f5de85d400a23798a42e48
https://pubmed.ncbi.nlm.nih.gov/15546274
https://pubmed.ncbi.nlm.nih.gov/15546274
Publikováno v:
Headache. 44(3)
Objective To provide medication price data and cost-reducing strategies for the acute treatment of migraine. Methods Retail prices for common acute care medications were found at http://www.drugstore.com. Cost-reduction tactics were obtained from lit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51d92a8b958639682387eb4ee2a5b6a6
https://pubmed.ncbi.nlm.nih.gov/15012668
https://pubmed.ncbi.nlm.nih.gov/15012668